Background: Meningiomas are the most common primary tumor of the central nervous system. The relationship between meningioma and progestins is frequently mentioned but has not been elucidated.
Introduction
Meningiomas are the most frequent primary tumors of the central nervous system in adults [1] . They are mostly benign [2] and slow growing neoplasms with a low recurrence rate after complete surgical removal. Several observations indicate hormonal regulation of tumor growth including female prevalence (2/3), frequent expression of progesterone receptors in approximately 70% of meningiomas and epidemiological evidence of an association between meningioma and pregnancy [3] , breast cancer and exogenous hormone use [4] [5] [6] . Indeed, synthetic progestins, including cyproterone acetate and megestrol acetate, have been implicated in meningioma growth with several case reports and series published in the literature [7] [8] [9] [10] . To explore the molecular landscape of progestin-associated meningiomas, we retrospectively selected patients operated for a meningioma and previously exposed to long-term progestin treatment, and performed targeted deep sequencing of the known frequently mutated genes in meningiomas and compared the observed mutational landscape to a control population of women with meningiomas.
Materials and methods
We retrospectively selected patients operated for a meningioma according to the following criteria: available tissue, previous progestin treatment for >1 year, available written informed consent. Patients' records were retrospectively reviewed and all clinical data were compiled in a single database by two authors (MP and CDM). This study was approved by the local institutional review board. All meningioma samples were centrally reviewed by two neuropathologists (FB and CV). The samples were classified and graded according to the 2016 World Health Organization (WHO) criteria [11] .
All exons of known frequently mutated genes in meningiomas [12] [13] [14] (ARID1A, AKT1, AKT3, ATRX, CHEK2, CREBBP, KDM5C, KDM6A,  KLF4, NF2, PRKAR1A, PDCD10, PIK3CA, PIK3R1, POLR2A, PTEN,  SMO, SMARCB1, SMARCE1, SUFU, TERT, TRAF7) were sequenced from the tumor samples using a custom, next-generation sequencing assay developed at the Institut du Cerveau et de la Moelle Epinière. Tumor DNA was extracted from paraffin-embedded tumor samples using the Thermo-Scientific Kit, according to the manufacturer's recommendations, and from frozen tissue using the QIAamp DNA mini kit (QIAGEN, Hilden, Germany). DNAs were quantified and qualified using a NanoVue Plus spectrophotometer (GE Healthcare Life Sciences, Pittsburgh, MA). Target regions were captured from fragmented genomic DNA samples using a custom SeqCap EZ choice kit (Nimblegen), and paired-end 75-base massively parallel sequencing was carried out on an Illumina NextSeq500, according to the manufacturer's protocols. Tumor DNA was submitted to target next generation sequencing for known frequently mutated genes in meningiomas and copy number alterations (chromosome 1, 10, 18 and 22).
Tissue sections were cut from formalin-fixed and paraffin-embedded tumor samples. Deparaffinization and immunolabeling of the sections were carried out by an automated slide stainer Ventana benchmark XT system V R (Roche, Basel, Switzerland) with Ventana detection kits and ancillary reagents using peroxidase with diaminobenzidin as chromogen, according to the manufacturer's instructions. The primary antibodies were a rabbit monoclonal antiestrogen receptor (clone SP1, Roche, Ventana Medical System) and a mouse monoclonal antiprogesterone receptor (clone 16, Leica). Two neuropathologists (FB and CV) analyzed the immunolabeling and evaluated the percentage of tumor cells that were immunopositive for estrogen receptor and progesterone receptor. Expression was considered significant if 2% or more of tumor cells were immunopositive.
For statistical comparisons, a published series of 775 meningiomas was used [13] . To obtain a matched cohort, meningiomas in men and Grade III tumors were excluded from this published series. The resulting series of 530 Grades I and II meningiomas in women was defined as the control population and used for statistical comparisons (Table 1) .
Fisher's exact tests were used to compare qualitative variables, with P < 0.05 considered as significant. Hierarchical clustering and multidimensional representations were used using Ward's method. Multiple logistic regression was used to assess independent variables associated with progestin-responsive meningiomas. All the analyses were carried out using R software packages (R foundation, Vienna, Austria).
Results
Forty female patients with long-term (mean: 15 years) progestin treatment (cyproterone acetate: 38 patients, megestrol acetate: 1 patient and chlormadinone acetate: 1 patient) with at least one operated meningioma were analyzed. Those 40 patients harbored a total of 72 meningiomas, more frequently located at the skull base (46/72, 64%) compared with the control population of meningiomas (241/481, 50%, P ¼ 0.03). Nineteen patients (48%) had multiple meningiomas (4 had 2, 15 had 3 or more), compared with 4.7% in the control population (25/530, P < 10 À12 ). Out of the 40 operated meningiomas 31 were Grade I and 9 (22%) were Grade II [versus 124/530 (23%) in the control population] [13, 15] , because of brain invasion (2 cases), elevated number of mitoses (3 cases), minor criteria (2 cases) and chordoid histology (2 cases) ( Table 2 ). Despite a follow-up of only 1.4 years, we observed three recurrences (in two Grade I and one Grade II) requiring radiotherapy.
The mutational profile is reported in Figure 1 . The most striking result was the unexpectedly high frequency of PIK3CA mutations [14/40 (35%) versus 18/530 (3%) in the control population P < 10 À8 ] [13] . The spectrum of point mutations found in PIK3CA-mutant progestin-associated meningiomas was similar to their unselected counterparts ( Figure 2A ) (see supplementary  Table S1 , available at Annals of Oncology online for additional information on PIK3CA mutations). PIK3CA-mutant tumors were mainly found at the skull base compared with PIK3CA-wt tumors in the control population [13/18 (72%) versus 240/483 (50%), P < 0.01] but this could not be confirmed in the progestinassociated meningiomas [11/14 (78%) versus 18/26 (69%) Figure 2B ) [13, 15] . When focusing only on skull base meningiomas, the frequency of PIK3CA mutations was still statistically higher in progestin-associated meningiomas than in unselected meningiomas [11/29 (38%) versus 13/240 (5%), P < 10
À5
]. Both PIK3CA-mutant and progestin-induced meningiomas were associated with younger age in the whole population (51 years versus 57 years, P ¼ 0.015 and 48 years versus 58 years, P < 5.10
). While alterations of the PIK3CA/PTEN pathway have been associated with progesterone, estrogen and androgen expression in most solid cancers [16] , we did not find mutations in PIK3R1, no loss or mutation of PTEN and the frequency of AKT1 mutations did not differ from the control population 4/40 (10%) versus 59/530 (11%), thus confirming the pivotal role of PIK3CA mutations in progestin-associated meningeal tumorigenesis [16] . Unsurprisingly, in progestin-associated meningiomas, progesterone receptors were statistically significantly more expressed compared with an unselected population of meningiomas (39/40 versus 366/443, P ¼ 0.01). In contrast, no significant difference was observed for estrogen receptor expression (9/40 versus 159/443, P > 0.10) [17] . In the control population of meningiomas, the two most frequent mutated genes are NF2 and TRAF7 [13] . In progestinassociated meningiomas, we observed a significantly lower frequency of NF2 mutations [3/40 (7.5%) versus 169/530 (32%), P < 0.001] and/or chromosome 22 loss [7/40 (17.5%) versus 153/322 (48%), P < 0.001] and a significantly higher frequency of TRAF7 mutations [16/40 (40%) versus 140/530 (26%), P < 0.001] ( Figure 2C ). In the control population, PIK3CA mutations are associated with TRAF7 mutations (P ¼ 0.0005). However, in the progestin group, TRAF7 mutations were not associated with PI3KCA mutations (5/14 versus 11/26, P ¼ 0.7), in contrast to the control population (13/18 versus 127/512, P < 10 À4 ) [13, 15] . When considering only patients with at least one skull base meningioma (n ¼ 34), TRAF7 mutations were not associated with PI3KCA mutations either (4/13 versus 11/21, P ¼ 0.3), while there was a trend in the control population (9/13 versus 99/227, P ¼ 0.088). Apart from PIK3CA mutations, TRAF7 mutations were associated with AKT1 and KLF4 mutations in the majority of the cases in the control population (92/ 140 ¼ 66%). In progestin-associated meningiomas, the rate of isolated TRAF7 mutations without AKT1 or KLF4 mutations was higher (11/16 ¼ 69%) than in the control population (48/140 ¼ 34%) (P ¼ 0.012). We found no SMO mutation in our cohort of progestin-associated meningiomas, while they are present 15%-28% of all anterior skull base meningiomas [13, 18] but this difference did not reach statistical significance (P ¼ 0.25). We found two mutations in genes mostly mutated in high-grade meningiomas ARID1A [19] and KDM5C [14] . The ARID1A mutation was found in a Grade II tumor with PIK3CA and TRAF7 mutations, while the KDM5C mutation was found in an NF2 mutant Grade I meningioma (Figure 1) .
Finally, to identify the independent factors associated with progestin-responsive meningiomas, we carried out a logistic regression analysis. We entered the main clinical and molecular characteristics. We found only two independent factors associated with progestin-associated meningiomas: PIK3CA mutation (P ¼ 5 Â 10
) and age (P ¼ 0.004) (supplementary Table S2 , available at Annals of Oncology online). We then carried out a hierarchical clustering on the whole population of the clinical and histological characteristics and molecular alterations. All the variables are reported in a correlation matrix (supplementary Figure S1 , available at Annals of Oncology online) showing all the association and correlations mentioned earlier.
Discussion
While several epidemiologic and observational studies have suggested a role for hormonal modulation in the development and progression of meningioma, the relationship between hormone intake and the molecular biology of the tumors has never been explored. Here, for the first time, we explore the molecular basis of progestin-associated meningiomas. We show that at least a fraction of progestin-associated meningiomas are characterized by a specific mutational landscape, defined by a reshuffle of frequencies of known mutated genes compared with the control population of meningiomas.
The main result of our study is the increased frequency of PIK3CA mutations (35%) in progestin-associated meningiomas compared with the control population. PIK3CA mutations were initially found in a selected population of patients in high-grade meningiomas [20] . Combining the two main next-generation sequencing studies on sporadic meningiomas actually available in the literature [13, 15] , 32 cases of PIK3CA mutant meningiomas have been reported. They occurred mostly in women (75%) and located at the skull base (75%; 44% at the anterior and 31% at the middle skull base).
Since their first description [21] , PIK3CA mutations have been found in a wide variety of human cancers, the most frequent being in women in a hormonal context and include endometrial carcinoma (37%), breast cancer (31%) and cervical carcinoma (27%) [16] . The co-occurrence of progestin treatment and PIK3CA mutations in meningiomas could be explained by a synergistic action on downstream intracellular signaling. This co-occurrence is supported by the statistical association between PIK3CA mutations and progesterone receptor expression in a large study conducted on human solid tumors [16] . Preclinical models [22] and clinical data [23] demonstrate that PIK3CA mutations activate the PI3K/ AKT/mTOR pathway. On the other hand, the effect of progestins on meningioma tumorigenesis is unknown. In endometrial carcinoma, progestins may have an antioncogenic effect and are used for the treatment of early stage of the disease in young women [24], while in progestin-driven breast cancer, early stages of tumor formation and carcinogenesis are mediated by RANK ligand [25] . In the absence of an obvious common downstream target, further studies are needed to determine the intracellular signaling pathways implicated in progestin-associated PIK3CA related meningioma tumorigenesis. While TRAF7 mutations were more frequent in progestinassociated meningiomas, they occurred independently of not only PIK3CA mutations but also AKT1 and KLF4 mutations, in contrast to the control population of meningiomas [13] . This result suggests that the TRAF7 and PIK3CA co-mutation is not synergistic in the context of progestin stimulation, while TRAF7-and PIK3CA-driven meningioma tumorigenesis are promoted separately. As TRAF7 functions are currently incompletely deciphered [26] , the role of progestin modulation in TRAF7-driven meningioma tumorigenesis remains to be elucidated. When considering the respective influence of AKT1 and KLF4 mutations compared with TRAF7 in the case of co-mutations, there is actually no evidence in the literature to determine which mutation is the most decisive in meningioma tumorigenesis. Nonetheless, in the light of the high frequency of isolated TRAF7 mutations in our cohort, the pivotal role of TRAF7 mutations should be explored. The analysis of several tumors from the same patient harboring at least one meningioma with TRAF7 mutation, which was not possible in our cohort, could help address this question.
Apart from hormones, another factor known to induce meningioma formation is radiation. Interestingly, two recent studies on low-dose (L) [27] and high-dose (H) [28] radiation-induced meningiomas (RIMs) demonstrated that contrary to progestinassociated meningiomas, RIMs are characterized by a high frequency of genomic variants affecting the NF2 gene, including intronic rearrangements of the NF2 gene in H-RIMs, and specific chromosomal aberrations such as chromosome 7p loss in L-RIMs. Interestingly, no mutation affecting TRAF7, PIK3CA, AKT1 or KLF4 was encountered in these two series of RIMs.
An interesting and unreported observation in this series is the high frequency (48%) of multiple meningiomas that is rather often encountered in tumor predisposition syndromes such as Neurofibromatosis type 2 [29] , SUFU [30] and SMARCB1 [31, 32] germline mutations. This relationship between exogenous hormone use and multiple meningioma formation suggests a critical role of progestin to induce the tumoral initiation of multiple specific meningeal cells, mostly at the skull base in multiple locations. The vulnerability of these cells could be linked to the different embryologic origin of the meninges, being mesoderm- derived at the skull base and neural crest-derived at the convexity [33] , where PIK3CA mutant progestin-associated meningiomas are rare. However, we were not able to analyze several PIK3CA-mutated tumors of the same patient to investigate if the multiple tumors were a single or multiple preexisting tumor clones or appeared strictly under hormonal influence. From a therapeutic point of view, it is noteworthy that two of three tumors that presented with recurrence harbored PIK3CA mutations. As there are drugs under development targeting PIK3CA with several clinical trials under way, this discovery could potentially lead to the possibility of adjuvant targeted therapy, specifically in skull base tumors when not amenable to complete surgical removal.
Conclusion
In conclusion, our results demonstrate a shift in the mutational landscape of progestin-associated meningiomas compared with a series of unselected tumors. While it has been demonstrated that environmental factors may influence the rate and type of mutations in certain cancers such as past smoking in lung cancer, associated with KRAS mutations [34] , and that certain mutations may be associated with certain histological subtypes as in breast cancer, where luminal A tumors are linked to PIK3CA mutations [35] , to our knowledge, the fact that hormonal factors may demonstrate a capacity to shift the mutational landscape for a determined tumor type at a specific location is a unique observation. [13, 15] . (B) 3D view of skull depicting the approximate location of PIK3CA mutant progestin-associated meningiomas. Grade I meningiomas are displayed in green dots circled in blue and Grade II meningiomes in green dots circled in orange (C) Venn diagram showing the relationship of mutations between NF2, TRAF7, SMO, AKT1 (E17K), KLF4 (K409Q), POLR2A and PIK3CA in progestin-associated (left, green) and unselected (right, orange) meningiomas. The circle labeled 'other' represents meningiomas without any of the major mutations discovered with next generation targeted sequencing. The Venn diagram for unselected meningiomas was constructed using previously published data [13] .
